2023-10-31 09:47Financial Overview - Total revenue for Q1-Q3 2023 reached 6.383 billion RMB, a decrease of 18.3% compared to 7.811 billion RMB in Q1-Q3 2022 [4] - Net profit attributable to shareholders was 2.210 billion RMB, down from 2.721 billion RMB in the previous year [26] - Adjusted net profit for the same period was 2.193 billion RMB, compared to 2.317 billion RMB in 2022 [26] Profitability Metrics - Gross margin for Q1-Q3 2023 was 54.1%, an increase of 7.2% from the previous year [4] - Net profit margin was 34.4%, reflecting a slight decrease of 0.2% year-on-year [4] - Adjusted net profit margin improved to 34.6%, up by 4.7% compared to 29.7% in 2022 [26] Cash Flow and Operational Performance - Cash flow from operating activities was 2.864 billion RMB, showing a 0.9% increase [4] - Excluding large orders, revenue from small molecule CDMO business grew by 66.5% year-on-year [10] Adjustments and Financial Metrics - The company provided adjusted financial metrics to better reflect operational performance, excluding non-recurring items [4] - Adjusted net profit and adjusted net profit margin are considered beneficial for understanding the company's core performance [4] Balance Sheet Highlights - Total assets as of Q3 2023 amounted to 19.764 billion RMB, up from 18.239 billion RMB in 2022 [33] - Total liabilities were reported at 2.292 billion RMB, a decrease from 2.544 billion RMB in the previous year [37] - Shareholders' equity increased to 17.472 billion RMB from 15.695 billion RMB in 2022 [37]